전신성 소아 특발성 관절염 시장 : 약제 종류별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 동향 분석, 경쟁 구도, 예측(2019-2031년)

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market Set to Touch USD 2.15 Billion by 2031

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market is growing primarily due to rising prevalence, biologic therapy advancements, improved diagnostics, growing awareness, supportive healthcare policies, and expanding treatment accessibility.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market size by value at USD 1.61 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market size to grow at a steady CAGR of 4.23%, reaching a value of USD 2.15 billion by 2031. Key drivers of Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market include the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and growing demand for advanced biologic therapies like IL-1 and IL-6 inhibitors. Technological advancements in diagnostic tools and personalized medicine approach support the further growth of Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market. Additionally, supportive government initiatives, improved healthcare infrastructure, and expanding access to specialty care contribute to the market expansion. Strategic collaborations and ongoing clinical trials also enhance treatment options and innovations in Global sJIA Market.

Opportunity - Expansion of Orphan Drug Designation Incentives

The growth of Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market is significantly driven by the expansion of orphan drug designation incentives. Regulatory bodies like the FDA and EMA offer benefits, such as market exclusivity, tax credits, and reduced development costs to encourage innovation in rare disease treatments. These incentives attract pharmaceutical companies to invest in sJIA therapies, accelerating research and development, enhancing drug availability, and ultimately improving patient outcomes in this underserved segment.

Injectable Segment Holds Largest Share of Global sJIA Market

The injectable segment holds the largest share of Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market. This dominance is driven by the widespread use of biologic therapies, such as IL-1 and IL-6 inhibitors, which are primarily administered via injection. Injectable treatments offer faster onset of action and improved efficacy in managing severe symptoms, making them the preferred choice among healthcare providers. Their ability to target specific inflammatory pathways contributes significantly to better disease control and patient outcomes.

Impact of Escalating Geopolitical Tensions on Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market

Escalating geopolitical tensions can disrupt Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market by affecting pharmaceutical supply chains, delaying clinical trials, and increasing regulatory hurdles across borders. Trade restrictions and instability may hinder access to essential biologic therapies and raw materials, impacting treatment availability. Additionally, economic uncertainty can reduce healthcare funding and limit patient access to advanced therapies. These challenges may slow innovation and global collaboration, ultimately affecting disease management and market growth in vulnerable regions.

Competitive Landscape

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market is highly fragmented, with numerous players serving the market. Major companies dominating the market are Novartis AG, Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and UCB S.A. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentations

2. Executive Summary

3. Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing Prevalence of Autoimmune Disorders in Children
    • 3.2.1.2. Advancements in Biologic and Targeted Therapies
    • 3.2.1.3. Rising Awareness and Early Diagnosis of sJIA
  • 3.2.2. Restraints
    • 3.2.2.1. High Cost of Biologic Treatments
    • 3.2.2.2. Limited Access to Specialized Healthcare in Developing Regions
    • 3.2.2.3. Side Effects Associated with Long-Term Medication Use
  • 3.2.3. Opportunities
    • 3.2.3.1. Expansion of Orphan Drug Designation Incentives
    • 3.2.3.2. Growing Investment in Personalized Medicine
  • 3.2.4. Challenges
    • 3.2.4.1. Regulatory Hurdles in Drug Approval Processes
    • 3.2.4.2. Need for Long-Term Efficacy and Safety Data
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market: Marketing Strategies

5. Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market Overview

• 5.1. Market Size & Forecast, 2019-2031
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share and Forecast
  • 5.2.1. By Drug Type
    • 5.2.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.2.1.2. Corticosteroids
    • 5.2.1.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    • 5.2.1.4. Biologics
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Injectable
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By End User
    • 5.2.4.1. Hospitals
    • 5.2.4.2. Specialty Clinics
    • 5.2.4.3. Homecare Settings
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia Pacific (APAC)
    • 5.2.5.4. Latin America (LATAM)
    • 5.2.5.5. Middle East and Africa (MEA)

6. North America Systemic Juvenile Idiopathic Arthritis (sJIA) Market

• 6.1. Market Size & Forecast, 2019-2031
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channels
  • 6.2.4. By End User
  • 6.2.5. By Country
    • 6.2.5.1. United States
    • 6.2.5.1.1. By Drug Type
    • 6.2.5.1.2. By Route of Administration
    • 6.2.5.1.3. By Distribution Channel
    • 6.2.5.1.4. By End User
    • 6.2.5.2. Canada
    • 6.2.5.2.1. By Drug Type
    • 6.2.5.2.2. By Route of Administration
    • 6.2.5.2.3. By Distribution Channel
    • 6.2.5.2.4. By End User

7. Europe Systemic Juvenile Idiopathic Arthritis (sJIA) Market

• 7.1. Market Size & Forecast, 2019-2031
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By End User
  • 7.2.5. By Country
    • 7.2.5.1. Germany
    • 7.2.5.1.1. By Drug Type
    • 7.2.5.1.2. By Route of Administration
    • 7.2.5.1.3. By Distribution Channel
    • 7.2.5.1.4. By End User
    • 7.2.5.2. United Kingdom
    • 7.2.5.2.1. By Drug Type
    • 7.2.5.2.2. By Route of Administration
    • 7.2.5.2.3. By Distribution Channel
    • 7.2.5.2.4. By End User
    • 7.2.5.3. Italy
    • 7.2.5.3.1. By Drug Type
    • 7.2.5.3.2. By Route of Administration
    • 7.2.5.3.3. By Distribution Channel
    • 7.2.5.3.4. By End User
    • 7.2.5.4. France
    • 7.2.5.4.1. By Drug Type
    • 7.2.5.4.2. By Route of Administration
    • 7.2.5.4.3. By Distribution Channel
    • 7.2.5.4.4. By End User
    • 7.2.5.5. Spain
    • 7.2.5.5.1. By Drug Type
    • 7.2.5.5.2. By Route of Administration
    • 7.2.5.5.3. By Distribution Channel
    • 7.2.5.5.4. By End User
    • 7.2.5.6. Belgium
    • 7.2.5.6.1. By Drug Type
    • 7.2.5.6.2. By Route of Administration
    • 7.2.5.6.3. By Distribution Channel
    • 7.2.5.6.4. By End User
    • 7.2.5.7. Russia
    • 7.2.5.7.1. By Drug Type
    • 7.2.5.7.2. By Route of Administration
    • 7.2.5.7.3. By Distribution Channel
    • 7.2.5.7.4. By End User
    • 7.2.5.8. The Netherlands
    • 7.2.5.8.1. By Drug Type
    • 7.2.5.8.2. By Route of Administration
    • 7.2.5.8.3. By Distribution Channel
    • 7.2.5.8.4. By End User
    • 7.2.5.9. Rest of Europe
    • 7.2.5.9.1. By Drug Type
    • 7.2.5.9.2. By Route of Administration
    • 7.2.5.9.3. By Distribution Channel
    • 7.2.5.9.4. By End User

8. Asia Pacific Systemic Juvenile Idiopathic Arthritis (sJIA) Market

• 8.1. Market Size & Forecast, 2019-2031
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By End User
  • 8.2.5. By Country
    • 8.2.5.1. China
    • 8.2.5.1.1. By Drug Type
    • 8.2.5.1.2. By Route of Administration
    • 8.2.5.1.3. By Distribution Channel
    • 8.2.5.1.4. By End User
    • 8.2.5.2. India
    • 8.2.5.2.1. By Drug Type
    • 8.2.5.2.2. By Route of Administration
    • 8.2.5.2.3. By Distribution Channel
    • 8.2.5.2.4. By End User
    • 8.2.5.3. Japan
    • 8.2.5.3.1. By Drug Type
    • 8.2.5.3.2. By Route of Administration
    • 8.2.5.3.3. By Distribution Channel
    • 8.2.5.3.4. By End User
    • 8.2.5.4. South Korea
    • 8.2.5.4.1. By Drug Type
    • 8.2.5.4.2. By Route of Administration
    • 8.2.5.4.3. By Distribution Channel
    • 8.2.5.4.4. By End User
    • 8.2.5.5. Australia & New Zealand
    • 8.2.5.5.1. By Drug Type
    • 8.2.5.5.2. By Route of Administration
    • 8.2.5.5.3. By Distribution Channel
    • 8.2.5.5.4. By End User
    • 8.2.5.6. Indonesia
    • 8.2.5.6.1. By Drug Type
    • 8.2.5.6.2. By Route of Administration
    • 8.2.5.6.3. By Distribution Channel
    • 8.2.5.6.4. By End User
    • 8.2.5.7. Malaysia
    • 8.2.5.7.1. By Drug Type
    • 8.2.5.7.2. By Route of Administration
    • 8.2.5.7.3. By Distribution Channel
    • 8.2.5.7.4. By End User
    • 8.2.5.8. Singapore
    • 8.2.5.8.1. By Drug Type
    • 8.2.5.8.2. By Route of Administration
    • 8.2.5.8.3. By Distribution Channel
    • 8.2.5.8.4. By End User
    • 8.2.5.9. Vietnam
    • 8.2.5.9.1. By Drug Type
    • 8.2.5.9.2. By Route of Administration
    • 8.2.5.9.3. By Distribution Channel
    • 8.2.5.9.4. By End User
    • 8.2.5.10. Rest of APAC
    • 8.2.5.10.1. By Drug Type
    • 8.2.5.10.2. By Route of Administration
    • 8.2.5.10.3. By Distribution Channel
    • 8.2.5.10.4. By End User

9. Latin America Systemic Juvenile Idiopathic Arthritis (sJIA) Market

• 9.1. Market Size & Forecast, 2019-2031
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By End User
  • 9.2.5. By Country
    • 9.2.5.1. Brazil
    • 9.2.5.1.1. By Drug Type
    • 9.2.5.1.2. By Route of Administration
    • 9.2.5.1.3. By Distribution Channel
    • 9.2.5.1.4. By End User
    • 9.2.5.2. Mexico
    • 9.2.5.2.1. By Drug Type
    • 9.2.5.2.2. By Route of Administration
    • 9.2.5.2.3. By Distribution Channel
    • 9.2.5.2.4. By End User
    • 9.2.5.3. Argentina
    • 9.2.5.3.1. By Drug Type
    • 9.2.5.3.2. By Route of Administration
    • 9.2.5.3.3. By Distribution Channel
    • 9.2.5.3.4. By End User
    • 9.2.5.4. Peru
    • 9.2.5.4.1. By Drug Type
    • 9.2.5.4.2. By Route of Administration
    • 9.2.5.4.3. By Distribution Channel
    • 9.2.5.4.4. By End User
    • 9.2.5.5. Rest of LATAM
    • 9.2.5.5.1. By Drug Type
    • 9.2.5.5.2. By Route of Administration
    • 9.2.5.5.3. By Distribution Channel
    • 9.2.5.5.4. By End User

10. Middle East & Africa Systemic Juvenile Idiopathic Arthritis (sJIA) Market

• 10.1. Market Size & Forecast, 2019-2031
  • 10.1.1. By Value (USD Million)
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By End User
  • 10.2.5. By Country
    • 10.2.5.1. Saudi Arabia
    • 10.2.5.1.1. By Drug Type
    • 10.2.5.1.2. By Route of Administration
    • 10.2.5.1.3. By Distribution Channel
    • 10.2.5.1.4. By End User
    • 10.2.5.2. UAE
    • 10.2.5.2.1. By Drug Type
    • 10.2.5.2.2. By Route of Administration
    • 10.2.5.2.3. By Distribution Channel
    • 10.2.5.2.4. By End User
    • 10.2.5.3. Qatar
    • 10.2.5.3.1. By Drug Type
    • 10.2.5.3.2. By Route of Administration
    • 10.2.5.3.3. By Distribution Channel
    • 10.2.5.3.4. By End User
    • 10.2.5.4. Kuwait
    • 10.2.5.4.1. By Drug Type
    • 10.2.5.4.2. By Route of Administration
    • 10.2.5.4.3. By Distribution Channel
    • 10.2.5.4.4. By End User
    • 10.2.5.5. South Africa
    • 10.2.5.5.1. By Drug Type
    • 10.2.5.5.2. By Route of Administration
    • 10.2.5.5.3. By Distribution Channel
    • 10.2.5.5.4. By End User
    • 10.2.5.6. Nigeria
    • 10.2.5.6.1. By Drug Type
    • 10.2.5.6.2. By Route of Administration
    • 10.2.5.6.3. By Distribution Channel
    • 10.2.5.6.4. By End User
    • 10.2.5.7. Algeria
    • 10.2.5.7.1. By Drug Type
    • 10.2.5.7.2. By Route of Administration
    • 10.2.5.7.3. By Distribution Channel
    • 10.2.5.7.4. By End User
    • 10.2.5.8. Rest of MEA
    • 10.2.5.8.1. By Drug Type
    • 10.2.5.8.2. By Route of Administration
    • 10.2.5.8.3. By Distribution Channel
    • 10.2.5.8.4. By End User

11. Competitive Landscape

• 11.1. List of Key Players and Their Offerings
• 11.2. Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market Share Analysis, 2024
• 11.3. Competitive Benchmarking, By Operating Parameters
• 11.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

12. Impact of Escalating Geopolitical Tensions on Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market

13. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 13.1. Novartis AG
• 13.2. Hoffmann-La Roche Ltd
• 13.3. Pfizer Inc.
• 13.4. Johnson & Johnson
• 13.5. AbbVie Inc.
• 13.6. Bristol-Myers Squibb Company
• 13.7. Eli Lilly and Company
• 13.8. Sanofi S.A.
• 13.9. Amgen Inc.
• 13.10. Regeneron Pharmaceuticals Inc.
• 13.11. F. Hoffmann-La Roche AG
• 13.12. GlaxoSmithKline plc
• 13.13. Takeda Pharmaceutical Company Limited
• 13.14. Merck & Co., Inc.
• 13.15. UCB S.A.
• 13.16. Other Prominent Players

14. Key Strategic Recommendations

15. Research Methodology

• 15.1. Qualitative Research
  • 15.1.1. Primary & Secondary Research
• 15.2. Quantitative Research
• 15.3. Market Breakdown & Data Triangulation
  • 15.3.1. Secondary Research
  • 15.3.2. Primary Research
• 15.4. Breakdown of Primary Research Respondents, By Region
• 15.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable